Tofacitinib
Indication
Active ankylosing spondylitis (NICE TA920)
NICE TA920 - Tofacitinib for treating active ankylosing spondylitis
Red
Brand:
Nice TA:
920
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Musculoskeletal system
Background
1.1 Tofacitinib is recommended as an option for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults, only if:
-
tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough and
-
the company provides tofacitinib according to the commercial arrangement.